Next Article in Journal
Correction: Loeber, Gerard. ISNS 9th International Symposium, The Hague, The Netherlands, September 11–14, 2016. Int. J. Neonatal Screen. 2016, 2, 5
Previous Article in Journal
Impact of Lower Screening TSH Cutoff Level on the Increasing Prevalence of Congenital Hypothyroidism
Article Menu

Export Article

Open AccessReview
Int. J. Neonatal Screen. 2017, 3(2), 8; https://doi.org/10.3390/ijns3020008

A Roadmap to Newborn Screening for Duchenne Muscular Dystrophy

1
Department of Pediatrics, Divisions of Neurology and Neuromuscular at Nationwide Children’s Hospital, Columbus, 43205 OH, USA
2
Parent Project Muscular Dystrophy, Hackensack, 07601 NJ, USA
3
Mark Krueger & Associates, Inc., New York, 10175 NY, USA
4
Center for Gene Therapy, Research Institute, Nationwide Children’s Hospital, Columbus, 43205 OH, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Peter C.J.I. Schielen
Received: 14 December 2016 / Revised: 25 February 2017 / Accepted: 28 March 2017 / Published: 7 April 2017
View Full-Text   |   Download PDF [1264 KB, uploaded 9 April 2017]   |  

Abstract

Duchenne muscular dystrophy (DMD) is the most common childhood form of muscular dystrophy, with an estimated frequency of 1:5000 live births. The impact of the disease presents as early as infancy with significant developmental delays, and ultimately loss of ambulation and respiratory insufficiency. Glucocorticoids are the only pharmacological agents known to alter the natural progression of the disease by prolonging ambulation, reducing scoliosis, and assisted ventilation. Introduction of therapy at an early age may halt the muscle pathology in DMD. In anticipation of the potentially disease-modifying products that are reaching regulatory review, Parent Project Muscular Dystrophy (PPMD) formally initiated a national Duchenne Newborn Screening (DNBS) effort in December 2014 to build public health infrastructure for newborn screening (NBS) for Duchenne in the United States. The effort includes a formalized national Duchenne Newborn Screening Steering Committee, six related Working Groups, a Duchenne Screening Test Development Project led by PerkinElmer, a program with the American College of Medical Genetic and Genomics’ Newborn Screening Translation Research Network (NBSTRN), and collaborations with other Duchenne partners and federal agencies involved in NBS. We herein review the organization and effort of the U.S. DNBS program to develop the evidence supporting the implementation of NBS for DMD. View Full-Text
Keywords: Duchenne; newborn screening; gene therapy; muscular dystrophy Duchenne; newborn screening; gene therapy; muscular dystrophy
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Al-Zaidy, S.A.; Lloyd-Puryear, M.; Kennedy, A.; Lopez, V.; Mendell, J.R. A Roadmap to Newborn Screening for Duchenne Muscular Dystrophy. Int. J. Neonatal Screen. 2017, 3, 8.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Neonatal Screen. EISSN 2409-515X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top